Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients
Cancer Chemotherapy and Pharmacology · 2024-11 · 94 (5) · 721-732
DOI: 10.1007/s00280-024-04707-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 23.08.2024. Verfasst von Xinyu Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Scientific Research Project of Heilongjiang Provincial Health and Health Commission, Health Development Promotion Project of Beijing Kangmeng Charity Foundation, Heilongjiang Postdoctoral General Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Trastuzumab is a potent targeted therapy drug for HER2-positive cancer patients. A comprehensive understanding of trastuzumab's mechanism of action, pharmacokinetic (PK) parameters, and steady-state exposure in different treatment regimens and administration routes is essential for a thorough evaluation of the drug's safety and effectiveness. Due to the distinctive pharmacokinetics, indications, and administration methods of trastuzumab, this understanding becomes crucial. Drug exposure can be assessed by measuring trastuzumab's peak concentration, trough concentration, or area under the curve through assays like enzyme-linked immunosorbent assay (ELISA) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). The dose-response (D-R) and exposure-response (E-R) relationships establish the correlation between drug dosage/exposure and the therapeutic effect and safety. Additionally, various covariates such as body weight, aspartate transaminase, and albumin levels can influence drug exposure. This review provides a comprehensive overview of trastuzumab's mechanism of action, data on steady-state concentration and PK parameters under multiple administration routes and indications, discussions on factors influencing PK parameters, and evaluations of the effectiveness and safety of E-R and D-R in diverse HER2-positive cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
- Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. jdyhmu3@163.com.
- Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. 13804567370@163.com.
Förderung
- Scientific Research Project of Heilongjiang Provincial Health and Health Commission
- Health Development Promotion Project of Beijing Kangmeng Charity Foundation
- Heilongjiang Postdoctoral General Program
Zitieren
APA
Luo, X., Wang, N., Xing, Y., Gao, X., Yu, Y., Liu, T., Jiang, S., & Dong, M. (2024). Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients. Cancer Chemotherapy and Pharmacology, 94(5), 721-732. https://doi.org/10.1007/s00280-024-04707-y
Vancouver
Luo X, Wang N, Xing Y, Gao X, Yu Y, Liu T, et al. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients. Cancer Chemotherapy and Pharmacology. 2024;94(5):721-732. doi:10.1007/s00280-024-04707-y
BibTeX
@article{Luo2024,
author = {Luo, Xinyu and Wang, Nan and Xing, Yue and Gao, Xinyue and Yu, Yang and Liu, Tong and Jiang, Shuai and Dong, Mei},
title = {Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
volume = {94},
number = {5},
pages = {721--732},
doi = {10.1007/s00280-024-04707-y}
}
EUVIMED